Advanced prostate cancer displays conspicuous chromosomal instability and rampant copy number aberrations, yet the identity of functional drivers resident in many amplicons remain elusive. Here, we implemented a functional genomics approach to identify new oncogenes involved in prostate cancer progression. Through integrated analyses of focal amplicons in large prostate cancer genomic and transcriptomic datasets as well as genes upregulated in metastasis, 276 putative oncogenes were enlisted into an in vivo gain-of-function tumorigenesis screen.
Introduction
Prostate cancer (PCa) is the most commonly diagnosed noncutaneous malignancy and the third leading cause of cancer mortality for men in the United States (1) . Bone is the most frequent site for distant metastasis of PCa, which inflicts significant morbidity and mortality (2) . Genomic profiling of PCa (3-7) has revealed overall lower mutation frequency compared with most solid cancer types (8) , yet advanced disease is characterized by rampant genomic rearrangements and somatic copy number alterations (SCNAs) (3) (4) (5) (6) (7) . SCNAs affect a larger fraction of the cancer genome than any other type of genetic alterations in cancer (9) , underscoring the potential role of SCNAs in driving the malignant nature of PCa. Functional driver genes residing within recurrent amplifications include key PCa oncogenes such as EZH2 on 7q36.1, MYC on 8q23-24, NCOA2 on 8q13.3, and AR on Xq12 (3) . Gainof-function screens of resident genes within amplicons is a proven approach in the identification of novel oncogenes.
In this study, our screen identified PYGO2 as a putative driver of PCa progression. PYGO2 is an essential transcription co-activator with β-catenin/TCF complex for the Wnt signaling pathway in Drosophila (10) . With a highly conserved plant homeodomain (PHD) in its Cterminus, PYGO2 binds to H3K4me and activates β-catenin-dependent transcriptional regulation (11) . Evidence suggests that PYGO2 modulates gene transcription through both Wnt-dependent and Wnt-independent mechanisms (11) . Emerging data indicate its pivotal role in multiple cancers including glioma (12) , breast cancer (13) , hepatic carcinoma (14) , and intestinal tumors (15) . Recently, PYGO2 expression was identified as a potential risk stratification marker for PSA progression in PCa following radical prostatectomy (16) . PYGO2 is recruited by PCGEM1, a long non-coding RNA, to enhance AR-bound enhancer activity (17) . Nevertheless, the functional contribution of PYGO2 to PCa progression, particularly bone metastasis, is not known, prompting us to explore its role in PCa biology.
Materials and Methods

Cell culture and patient-derived xenograft models
The LHMK cell line was a generous gift from William Hahn (18) . LHMK and 293T (obtained from ATCC) were maintained in DMEM, 10% FBS. Prostate cancer cell lines PC-3, LNCaP, C4, C4-2, DU145 and 22Rv1 were obtained from ATCC and maintained in RPMI640, 10% FBS. L cells and L Wnt-3A cells were obtained from ATCC and maintained in DMEM, 10% FBS (for L Wnt-3A cells, 0.4 mg/ml G-418 was supplemented). ATCC provides the Human STR Profiling Cell Authentication Service to authenticate these cell lines. All cells were routinely verified as being free of mycoplasma using MycoAlert Mycoplasma Detection Kit (Lonza). Patient-derived xenograft (PDX) models were previously published and generous gifts from Dr. Nora Navone (19, 20) . The scramble control shRNA and PYGO2-targeting shRNA were ordered from Sigma, with sequences listed in Supplementary Table S1 .
Generation of LHMK sublines for screening
The ORF lentiviral vectors in the Precision LentiORF collection were obtained from the Functional Genomics Facility at MD Anderson Cancer Center. In 96-well plates, we packaged 288 ORF lentiviruses individually and infected low-passage LHMK cells. Stable sublines were generated by blasticidin selection, with each sub-line individually expanded for the in vivo screen.
In vivo ORF screen
To evaluate the tumorigenicity of the parental cell line, LHMK cells were injected subcutaneously with 10 6 viable cells in a mixture of PBS:Matrigel (BD Biosciences) in NCr nude mice (Taconic), which did not form tumors 6 months post implantation. Expecting a small fraction of the candidate genes to promote tumorigenesis, we designed a multi-site subcutaneous inoculation method to reduce the number of mice needed for the screen. For each LHMK-ORF sub-line, 10 6 viable cells, resuspended in 50μL mixture of PBS:Matrigel, were injected subcutaneously into pre-labeled flank positions of mice (5 sites on each side of flank, so total 10 sites per mouse). The experiment was designed so that each subline was evaluated in 10 different mice, and each mouse received injections from 10 different sublines. Mice were monitored for tumor formation via caliper measurement for 8 months. We did not observed formation of more than two subcutaneous tumors on any mice in the screen. All animal experimental protocols were approved by the IACUC at MD Anderson Cancer Center.
Tissue specimens, histology and western blot
A prostate cancer tissue microarray with 80 cases and Gleason grade information was purchased (PR803b, US Biomax). Archived prostate cancer FFPE specimens of adjacent normal, primary tumor and metastasis (total n = 49) were requested from MD Anderson Cancer Center Prostate Cancer SPORE program (Specialized Programs of Research Excellence) under approved IRB protocol at MD Anderson Cancer Center. For all clinical samples, written informed consent was obtained from the patients. The studies were conducted in accordance with recognized ethical guidelines (Declaration of Helsinki, CIOMS, Belmont Report, U.S. Common Rule). H&E stain, immunohistochemical (IHC) and western blot were performed as previously described (21) . Primary antibodies used include PYGO2 (HPA023689, Sigma, for IHC; GTX119726, GeneTex, for western blot), KRAS (sc-30, Santa Cruz), FGFR1, β-Catenin, c-Myc, Met, H3K4me2, H3K4me3, H3 (9740, 8480, 5605, 8198, 9725, 9751 and 4499, Cell Signaling Technology), β-actin (A2228, Sigma).
Cell proliferation and soft agar assay
For 2D proliferation, cells were seeded to 24-well plates with confluence tracked by IncuCyte (Essen BioScience) for 3 days. For soft agar assay, DMEM with 1% FBS, 0.6% LE Agarose (Lonza) was used as base layer while cells were seeded in 2×10 4 cells/mL in DMEM with 1% FBS, 0.3% SeaPlaque Agarose as top layer (Lonza). After incubated at 37°C for 3 weeks, the colonies were stained by crystal violet and quantified.
Migration and invasion assay
Cells were first starved in DMEM with 1% FBS overnight and then seeded in serum-free DMEM at 5×10 5 cells/200μL to the chamber inserts (BD Falcon) for migration or BioCoat Matrigel Invasion Chamber (BD Falcon) for invasion. DMEM with 10% FBS were placed at the bottom as chemoattractant. Migrated or invaded cells on the membrane were stained with crystal violet for quantification.
Quantitative RT-PCR
RNA was isolated by RNeasy Kit (Qiagen) and reversed transcribed using Superscript III cDNA synthesis Kit (Life Technology). Quantitative PCR was performed using SYBR-GreenER Kit (Life Technology). Primers are listed in Supplementary Table S1 .
Functional validation using animal models
Experimental bone metastasis assay using intracardiac injection and noninvasive imaging was performed as previously reported (22) . PDX models were passaged in the flank of C.B-17 SCID (Taconic) mice as previously reported (19, 20) . The tumors were measured by caliper and treated by intratumoral injection of 10μg siRNA targeting PYGO2 (Sigma-Aldrich, SASI_HS01_00059018, or 1:1 ratio of SASI_Hs01_00059021 and SASI_Hs02_00363399) or control siRNA (Sigma-Aldrich, SIC001) twice a week, using MaxSuppressor In Vivo RNA-LANCEr II (Bioo Scientific) following the manufacturer's protocol and our recent report (23) .
Luciferase reporter assay
TCF/LEF reporter plasmids, M50 Super 8x TOPFlash and M51 Super 8x FOPFlash (TOPFlash mutant), were gifts from Randall Moon (24) (Addgene plasmid # 12456, 12457). Activation of Wnt/β-catenin signaling was achieved by using conditioned medium from Wnt3A-secreting L cells and control L cells (25) . PC3 sublines were transfected with Lipofectamine LTX Reagent (Life Technologies) following manufacturer's protocol and the reporter assay was performed as described (26) . Lu 
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Statistical Analysis
Unless otherwise indicated, data represent mean ± s.d., with Student's t-test assuming twotailed distributions used to calculate statistical significance between groups. P<0.05 was considered statistically significant (annotation: *P < 0.05, **P < 0.01, ***P < 0.001, # P > 0.05). To display PYGO2 expression from four Oncomine transcriptomic datasets containing primary and metastatic PCa samples (3, 4, 27, 28) , log2 median-centered ratio of PYGO2 probe data were drawn as Box plot with whiskers displaying 10-90 percentile using GraphPad Prism.
Results
In vivo ORF screen identified putative genes involved in prostate cancer progression
To enlist genes with putative function in promoting PCa progression, we performed an integrated oncogenomic analysis to enrich for cancer-relevant genes and cull passenger genes. First, genes with focal copy number gains were identified using GISTIC2 (29) Fig. 1 ). This analysis resulted in 6909 genes which were further selected based on two filters: genes with copy number correlated expression in at least 1 of the 4 datasets (P<0.01) and genes with higher expression in metastasis compared with primary tumor (P<0.05) in at least 3 out of 8 Oncomine transcriptomic datasets (3, 4, 27, (30) (31) (32) (33) (34) . The gene expression data for these 8 datasets were directly queried from Oncomine (35) . After applying the filters, 394 genes remained ( Fig. 1 ). Second, to enrich for genes potentially contributing to metastasis, 363 genes upregulated in metastasis compared with primary tumor were identified in at least 6 out of 8 Oncomine datasets. Third, 77 amplified genes were identified from integrated analysis of our previous telomerase reactivation PCa mouse model and human PCa genomics (36) . From these diverse datasets and experimental systems, a total of 741 putative metastasis-promoting genes were identified ( Supplementary Table S2 ), among which 288 ORFs (corresponding to 276 unique genes) were available at the time of experimentation from the Precision LentiORF Collection for lentiviral overexpression and ORF screening ( Supplementary Table S3 ).
We employed LHMK cells for the in vivo screen, which were derived from primary human prostate epithelial cells after immortalization with SV40 LT and hTERT followed by transformation with MYC and PI3K (18) . LHMK cells exhibit very limited tumorigenic capability when inoculated orthotopically or subcutaneously in nude mice (18) , providing a suitable system to identify putative oncogenes through a gain-of-function approach. ORFencoded lentivirus was packaged in 96-well plates and used to transduce LHMK cells, followed by blasticidin selection, to establish 288 individual ORF-expressing sublines ( Fig.  2A ). Overexpression of Red Fluorescent Protein (RFP) in the same LentiORF backbone was used as negative control (Fig. 2B ). ORFs encoding KRAS and FGFR1 were used as positive controls (Fig. 2C ), the choice of which was justified given the PCa-promoting role of RAS/ MAPK (3, 37) or FGF/FGFR1 signaling, respectively (38) . ORF-driven overexpression was validated for a number of randomly selected genes using quantitative RT-PCR ( Supplementary Fig. S1A ) which all showed various levels of overexpression of the putative targets. In the screen, the 288 sublines and RFP control subline were inoculated into mice subcutaneously (n=10 for each ORF). Mice were monitored for tumor development for 8 months. While no tumor growth was detected for the RFP control (total 30 sites were tested), the positive controls KRAS and FGFR1 generated 100% and 30% incidence of tumors, respectively ( Supplementary Table S4 ). Importantly, 38 genes were identified as positive hits based on a 10-50% tumor incidence rate ( Supplementary Table S4 ), among which 10 genes produced more than 2 tumors out of the 10 tested sites (Fig. 2D , Supplementary Fig. S1B ). The top 10 hits include EZH2, known to be frequently upregulated in advanced PCa and to promote metastasis, and CCNE2 which is overexpressed in metastatic PCa and critical for cell cycle G1/S transition (39) . Notably, the presence of known PCa-promoting genes among the top hits suggests the possibility that the other genes may represent bona fide oncogenes involved in PCa progression. To rule out the possibility that the negative hits were merely due to failure of LentiORF-driven gene overexpression, we randomly selected 26 negative hits from the lenti-ORF infected cells and showed that 23 out of 26 genes were upregulated more than 2-fold ( Supplementary Fig.  S1C ).
Reasoning that in vitro assays could complement the in vivo result to illuminate biological effects, we performed proliferation, migration and invasion assays for the sublines of the top hits. While meager differences were observed in the two-dimensional (2D) growth curve assay (Fig. 3A) , soft-agar assay showed that sublines overexpressing genes like KRAS, PYGO2, MOS, CCNE2 and MTBP could form significantly more colonies than RFP control (Fig. 3B ). The gain of colony formation potential by genes such as PYGO2, MOS and MTBP (with functions in PCa uncharacterized) was accompanied by their effect on increased migration and invasion (Fig. 3C,D) . Together, the robustness of PYGO2 in the in vivo ORF screen coupled with strong effect in the 3D colony assay (second only to KRAS) ( Fig. 3B ) prompted further functional investigation of this putative PCa promoting gene.
Overexpression of BOP1 (block of proliferation 1) led to strongest enhancement of migration and invasion (Fig. 3C,D) . Located at 8q24.3, BOP1 is close to MYC at 8q24.21.
These two genes tend to co-amplified in the broad amplification peak at 8q24 ( Supplementary Fig. S1D ), which is commonly attributed to the oncogenic function of MYC. Therefore, we reasoned that the amplification of BOP1 might be, at least partly, a passenger effect from MYC amplification, which would make a study on BOP1 less significant in terms of finding independent biomarker and/or therapeutic target for PCa. TOMM40L overexpression led to higher tumor incidence rate and shorter onset day than PYGO2 (Fig. 2D ). The function of TOMM40L was not studied before. The commercially available reagents for TOMM40L are limited, making it difficult to perform clinical characterization of its expression and related functional studies. Fig. 4A ). In the TCGA dataset, PYGO2 gain/amplification is associated with higher Gleason score in 
PYGO2 expression is correlated with higher Gleason score and bone metastasis
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Author Manuscript treatment-naïve primary PCa (Fig. 4B) , as well as shorter disease-free survival and shorter biochemical recurrence (Fig. 4C ). Copy number correlated expression of PYGO2 is evident across several datasets ( Supplementary Fig. S2A ). Regarding metastasis, PYGO2 is significantly upregulated at the transcriptional level in metastatic PCa compared with primary tumors (Fig. 4D) . At the protein level, tissue microarray (TMA) analysis showed that, while PYGO2 expression was not detectable in normal prostate, stronger PYGO2 expression was correlated with higher Gleason score (Fig. 4E ). Furthermore, from an archived clinical PCa sample cohort at MD Anderson Cancer Center which includes normal, primary tumors, lymph node metastases and bone metastases, IHC analysis showed that PYGO2 expression was highly upregulated in metastases (Fig. 4F) . The clinical expression analysis, in addition to the in vivo functional screen and in vitro functional validation, strongly support a direct role of PYGO2 in promoting PCa progression.
PYGO2 overexpression promotes prostate tumor growth and invasion to lymph nodes
To determine if PYGO2 upregulation enhances PCa progression, we first re-tested the LHMK sublines expressing RFP or PYGO2 by subcutaneous inoculation in NSG mice. The LHMK-PYGO2 subline formed significantly larger tumors as compared to RFP controls ( Fig. 5A, Supplementary Fig. S2B ). To test the pro-tumor function of PYGO2 in a different PCa cell line, we overexpressed PYGO2 in LNCaP, which also has a low endogenous level of PYGO2 (Fig. 5B ). Compared with GFP control, PYGO2 overexpression led to significant increase of subcutaneous tumor weight ( Fig. 5B) . Based on the IRES-GFP cassette in the overexpression vector, we identified GFP + tumor cells in draining lymph nodes in 3 out of 10 mice inoculated with LNCaP-PYGO2 cells (Fig. 5C, Supplementary Fig. S2C ). Thus, PYGO2 overexpression promotes both primary tumor growth and regional lymph node invasion.
PYGO2 depletion inhibits prostate cancer metastasis and PDX tumor growth
To determine whether PYGO2 is required for PCa progression, we used two independent PYGO2 shRNA vectors to deplete PYGO2 levels in the aggressive PCa cell line PC3 (45) (Fig. 6A ). PYGO2 knockdown resulted in modest decrease in cell proliferation in vitro ( Supplementary Fig. S3A ) but significant reduction of cell invasion ( Supplementary Fig.  S3B ). When inoculated subcutaneously in mice, PYGO2 knockdown cells showed reduced tumorigenic potential (Fig. 6B ). To evaluate whether PYGO2 knockdown affects spontaneous metastasis of PC3 to lung, we removed the subcutaneous tumors at Day 50 post-inoculation and assessed metastasis formation in lung 2 months later by gross inspection and histology. While 60% of mice previously inoculated with the PC3-shControl subline developed spontaneous lung metastasis nodules, less than 20% of mice inoculated with the shPYGO sublines of PC3 developed lung metastasis nodules ( Fig. 6C , Supplementary Fig. S3C ). Expression of PYGO2 in PC3 cells remains pronounced in lung metastasis ( Supplementary Fig. S3D ).
As bone is the most frequent site of distant metastasis of PCa, we performed intracardiac injection to compare the bone colonization capability of shControl and shPYGO2 sublines of PC3 after labeling PC3 with a triple reporter (TR) containing firefly luciferase, GFP and thymidine kinase (46) . Noninvasive bioluminescence imaging revealed that PYGO2 knockdown impaired the ability of PC3-TR cells to colonize the bone and form osteolytic lesions ( Fig. 6D-F ). PYGO2 is also expressed by a few other PCa cell lines, including 22Rv1, C4 and C4-2 ( Supplementary Fig. S3E ).
As PDX models more closely resemble the clinical disease, we examined the effect of targeting PYGO2 in two PDX models: MDA-PCa-180 (derived from primary CRPC) (19) and MDA-PCa-118b (derived from bone metastatic CRPC) (20) . We first performed IHC for PYGO2 and detected high PYGO2 expression in both models (Fig. 7A) . Through intratumoral infusion of siRNA (either scramble control or PYGO2-targeting), we were able to significantly attenuate PYGO2 protein level (Fig. 7B) . In both models, PYGO2-targeting siRNA treatment inhibited subcutaneous PDX tumor growth ( Fig. 7C) . For MDA-PCa-180, we also demonstrated the anti-tumor effect by an independent siRNA mixture ( Supplementary Fig. S3F ). Spontaneous metastasis to lung or bone from the PDX tumors was not detected based on histological evaluation, and metastasis was not reported to occur in these two models previously (19, 20) . These results support PYGO2 as a therapeutic target for PCa.
To explore the function of PYGO2 as a co-activator of the Wnt/β-catenin pathway in the context of PCa, we compared the ability of PC3-shControl and PC3-shPYGO2 sublines to activate the Wnt/β-catenin reporter TOPFlash (24) under conditioned medium from L Wnt-3A cells (25) . As control, FOPFlash and conditioned medium from L cells were used. Interestingly, PYGO2 knockdown significantly reduced the Wnt-3A-induced TOPFlash activity (Fig. 7D) . At the protein level, PYGO2 knockdown moderately decreased expression of β-catenin and Wnt/β-catenin targets c-Myc and Met (Fig. 7E ). PYGO2 knockdown affected little on H3K4me2 and H3K4me3 levels (Fig. 7E ). Our results on the connection of PYGO2 with Wnt signaling was supported by the gene set enrichment analysis (GSEA) showing that Wnt pathway is enriched in both localized PCa and CRPC samples with high PYGO2 expression phenotype (Fig. 7F ).
Discussion
In summary, through functional screen and analysis of recurrently amplified genes in PCa, we identified PYGO2 as a PCa-promoting gene capable of driving disease progression and metastasis. Another candidate PCa gene located on 1q21.3, CREB3L4 (a.k.a. AIbZIP, an androgen-regulated gene), has been reported as highly expressed in PCa (47) . However, CREB3L4 is distinct in that its expression is neither correlated with copy number gain (3) nor upregulated in metastatic PCa when we surveyed the 8 Oncomine datasets (P>0.5 for all datasets). In fact, CREB3L4 was not among the 60 of 178 genes located in 1q21.2-q22 with transcript levels correlated with copy number gain (3). From the 60 genes in 1q21.2-q22, 13 genes passed our gene selection filters and 6 genes (ENSA, LYSMD1, RPRD2, FLAD1, KRTCAP2, and PYGO2) were screened with available lentiviral ORFs. Only PYGO2 emerged as a functional hit in our tumor models. Our results indicate that PYGO2 promotes primary tumor growth, lymph node invasion and bone metastasis. Together, we conclude that PYGO2 is a key driver gene of 1q21.3 that is targeted for increased expression via copy number gain in PCa.
Hyperactivated Wnt signaling pathway has been increasingly identified to play important roles in promoting advanced prostate cancer, including the metastatic process and development of castration-resistant prostate cancer (48) . Therefore, the implication of PYGO2 in Wnt pathway has significant clinical relevance. Future studies to investigate the molecular mechanism of PYGO2 in PCa progression will provide new opportunities to target lethal PCa. We envision at least two potential approaches to target PYGO2. First, the PHD finger in PYGO2 is responsible for binding to di-and trimethylated lysine 4 of histone H3 (H3K4me2/3). Therefore, small molecule inhibitors blocking the PHD finger (49) may serve as useful agents for PYGO2-overexpressed lethal PCa. Second, siRNAs that effectively downregulate PYGO2 in vivo may provide another avenue. siRNA or shRNA as therapeutics is being actively developed, although challenges remain in the delivery of these agents. That said, recent progress using exosomes to deliver siRNA or shRNA in vivo (50) marks a new direction for moving this idea forward.
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